![]() ![]() ![]() Lubitz, MD, MPH, senior author of the paper alongside Jagpreet Chhatwal, PhD (both Massachusetts General Hospital, Boston). “This essentially means that, in this strategy, the device is doing the initial screening for atrial fibrillation on the user in the background,” said Steven A. With this approach, the device-provided information was confirmed by the patient using a wearable electrocardiographic monitor for a 2-week period. Yet the best strategy-with an incremental cost-effectiveness ratio of $57,894 per quality-adjusted life-year (QALY), below the acceptability threshold of $100,000-involved wrist-worn wearables equipped with both photoplethysmography (PPG), which uses light to detect an irregular pulse, as well as a single-lead ECG. This was true not only for the wearable tech, where concerns have been raised about the potential for greater consumption of healthcare resources, but also for the more-traditional pulse palpation and 12-lead ECG. Nearly all screening strategies were an improvement upon not screening at all. Wrist-worn devices like smartwatches and fitness trackers appear to be cost-effective ways of screening for atrial fibrillation (AF) among high-risk people ages 65 and up, according to results of a new modeling study.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |